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A B S T R A C T
The effect of poly(2-ethyl-butyl cyanoacrylate) nanoparticles containing the cytotoxic drug cabazitaxel was
studied in three breast cancer cell lines and one basal-like patient-derived xenograft model grown in the
mammary fat pad of immunodeficient mice. Nanoparticle-encapsulated cabazitaxel had a much better efficacy
than similar concentrations of free drug in the basal-like patient-derived xenograft and resulted in complete
remission of 6 out of 8 tumors, whereas free drug gave complete remission only with 2 out of 9 tumors. To
investigate the different efficacies obtained with nanoparticle-encapsulated versus free cabazitaxel, mass spec-
trometry quantification of cabazitaxel was performed in mice plasma and selected tissue samples. Nanoparticle-
encapsulated drug had a longer circulation time in blood. There was approximately a three times higher drug
concentration in tumor tissue 24 h after injection, and two times higher 96 h after injection of nanoparticles with
drug compared to the free drug. The tissue biodistribution obtained after 24 h using mass spectrometry analyses
correlates well with biodistribution data obtained using IVIS® Spectrum in vivo imaging of nanoparticles labeled
with the fluorescent substance NR668, indicating that these data also are representative for the nanoparticle
distribution. Furthermore, immunohistochemistry was used to estimate infiltration of macrophages into the
tumor tissue following injection of nanoparticle-encapsulated and free cabazitaxel. The higher infiltration of
anti-tumorigenic versus pro-tumorigenic macrophages in tumors treated with the nanoparticles might also
contribute to the improved effect obtained with the nanoparticle-encapsulated drug. Tumor infiltration of pro-
tumorigenic macrophages was four times lower when using nanoparticles containing cabazitaxel than when
using particles without drug, and we speculate that the very good therapeutic efficacy obtained with our ca-
bazitaxel-containing particles may be due to their ability to reduce the level of pro-tumorigenic macrophages in
the tumor. In summary, encapsulation of cabazitaxel in poly(2-ethyl-butyl cyanoacrylate) nanoparticles seems
promising for treatment of breast cancer.
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Chemotherapy has during recent years improved the treatment and
prognosis of different cancers, but the therapeutic effect is not sufficient
for certain cancer types and the treatment may also result in unwanted
side effects. Several products of drug-loaded NPs have reached the
market, and many new product candidates are in clinical trials. These
aspects, including the challenges and opportunities of using nano-
particles in cancer drug delivery, have been discussed in several reviews
[1,2]. In addition to improving efficacy by benefiting from the en-
hanced permeability and retention (EPR) effect [3], NP encapsulated
drug delivery may demonstrate reduced toxicity. The main advantage
of the drug-loaded NPs that have reached the market is that they give
less adverse effects than free drug, while the therapeutic efficacy is
rather similar [4].
Poly(alkyl cyanoacrylate) (PACA) was first developed and approved
as surgical glue, and has later demonstrated promising abilities as a
drug carrier, being biodegradable and allowing high drug loading ca-
pacity [5]. We have earlier shown that the degradation rate of PACA
NPs can be controlled by the choice of the alkyl chain of the cyanoa-
crylate monomer [6], and we recently demonstrated, using a panel of
cell lines, that the cytotoxicity was dependent on the monomers used,
i.e. n-butyl-, 2-ethyl-butyl-, or octyl cyanoacrylate (PBCA, PEBCA and
POCA, respectively) [7]. Based on this experience the present study was
initiated to evaluate the effect of PEBCA NPs in breast cancer.
The PEBCA NPs used in this study contain the cytotoxic drug ca-
bazitaxel (CBZ), a semi-synthetic taxane derivative which inhibits mi-
crotubule disassembly [8]. CBZ is approved by the US Food and Drug
Administration (FDA) for treatment of refractory prostate cancer as a
second line drug after docetaxel chemotherapy [9,10]. One advantage
of CBZ is its low affinity for P-glycoprotein, thus reducing the possibi-
lity of obtaining drug resistance [8,11]. The very low water solubility of
CBZ complicates administration of the free drug. However, the ex-
cellent compatibility and solubility of CBZ in alkyl cyanoacrylate
monomer solution allows for encapsulation of high concentrations of
the drug in PACAs. The NPs were surface modified with the poly-
ethylene glycol (PEG)-containing molecules Pluronic F68 and Kolliphor
HS15 to obtain an increased circulation time after intravenous (i.v.)
injection [12].
Breast cancer can be classified into major subgroups based on the
gene expression pattern. Tumors belonging to the most aggressive
subtypes are commonly treated with antracycline- and taxane-based
chemotherapy regimens. In particular, for hormone receptor and HER2
negative (often basal-like) tumors no targeted therapies are available,
and the patients would therefore benefit from improved chemotherapy
regimens [13]. One strategy may be to use NPs as encapsulation of
doxorubicine in liposomes has been reported to increase drug uptake
into breast cancer [14,15]. In the current study, the growth inhibitory
effect of CBZ encapsulated into PEBCA NPs was evaluated in breast
cancer models in vitro and in vivo. Three breast cancer cell lines re-
presenting the two main types of breast cancer, the luminal and basal-
like subgroups, were used. One of the cell lines was also injected and
grown in the mammary fat pad of immunodeficient mice. Additionally,
one patient-derived xenograft (PDX) model previously demonstrated to
be triple negative and representative for aggressive basal like breast
cancer [16] was included in the study.
The main finding is the improved therapeutic effect of PEBCA-CBZ
compared to free CBZ (i.e. the Jevtana® formulation) demonstrated in
the basal-like PDX model. Immunohistochemical staining revealed a
lower content of pro-tumorigenic macrophages in the PEBCA-CBZ
treated tumors than in tumors treated with free CBZ, which may partly
explain the improved efficacy. To elucidate the difference in efficacy of
PEBCA-CBZ and free CBZ, we also showed in vivo biodistribution of
particles loaded with the lipophilic fluorescent substance NR668.
Furthermore, we used quantitative LC-MS/MS analyses to describe the
biodistribution of CBZ in tissues and the kinetics of CBZ in blood plasma
after injection of both PEBCA-CBZ and free CBZ.
2. Materials and methods
2.1. Synthesis and characterization of nanoparticles
PEGylated PEBCA NPs were synthesized by miniemulsion poly-
merization. An oil phase consisting of 2.5 g 2-ethylbutyl cyanoacrylate
(monomer, Cuantum Medical Cosmetics, Spain) containing 0.2% (w/w)
butylated hydroxytoluene (Fluka, Switzerland), and 2% (w/w) Miglyol
812 (Cremer, USA) was prepared. Fluorescent particles for optical
imaging were prepared by adding NR668 (modified Nile Red) [17],
custom synthesis, 0.2% (w/w) to the oil phase. Particles containing
cytostatic drug for treatment were prepared by adding CBZ (10% (w/
w), Biochempartner Co. Ltd., China, product item number BCP02404)
to the oil phase, whereas vanillin (10% (w/w), Sigma-Aldrich, France)
was used as an inert model drug in control particles.
An aqueous phase consisting of 0.1M HCl (20ml) containing
Pluronic F68 (2mM, Sigma, USA) and Kolliphor HS15 (6mM, Sigma,
Germany) was added to the oil phase and immediately sonicated for
3min on ice (6× 30 sec intervals, 60% amplitude, Branson Ultrasonics
digital sonifier 450, USA). The solution was rotated (15 rpm, SB3 ro-
tator, Stuart, UK) at room temperature overnight before adjusting the
pH to 5 using 1M NaOH. The polymerization was continued for 5 h at
room temperature on rotation. The dispersion was dialyzed (Spectra/
Por dialysis membrane MWCO 100,000 Da, Spectrum Labs, USA)
against 1 mM HCl to remove unreacted PEG. The size, polydispersity
index (PDI) and the zeta potential of the NPs were measured by dy-
namic light scattering and laser Doppler Micro-electrophoresis using a
Zetasizer Nano ZS (Malvern Instruments, UK). To calculate the amount
of encapsulated drug, the drug was extracted from the particles by
dissolving them in acetone (1:10), and quantified by liquid chromato-
graphy coupled to mass spectrometry (LC-MS/MS) as described below.
2.2. CBZ quantification by LC-MS/MS
CBZ, as the pure chemical or part of NPs, was quantified by LC-MS/
MS, using an Agilent 1290 HPLC system coupled to an Agilent 6490
triple quadrupole mass spectrometer. The HPLC column was an
Ascentis Express C8, 75× 2.1mm, 2.7 μm particles size with a
5×2.1mm guard column of the same material (Sigma), run at 40 °C.
Eluent A was 25mM formic acid in water and eluent B was 100%
methanol, and flow rate was 0.5ml/min. The mobile phase gradient
was isocratic at 55% B for 1.5min, then from 55% to 80% B over 1min,
followed by 1min washout time and subsequently column re-equili-
bration. Injection volume was 5.00 μl. MS detection was in positive ESI
mode (Agilent Jetstream) quantified in multiple reaction monitoring
(MRM) mode using the transition m/z 858.3 → 577.2. The parent ion
was chosen to be the Na adduct as this gave the best sensitivity.
Similarly, the hexadeuterated internal standard was detected on the
864.4 → 583.2 transition. Both analytes were run at 380 V fragmentor
and 20 V collision energy.
Reference standards were used for accurate quantification. The
unlabeled CBZ standard was the same as used for synthesis (see above)
at> 98% purity. Hexadeuterated CBZ internal standard was purchased
from Toronto Research Chemicals (Toronto, Canada; catalogue number
C046502 at 99.6% isotopic purity). Standards were dissolved in acetone
and were used to build an unlabeled standard series spanning at least
five concentration points
The limit of quantification (LOQ) was calculated from six replicate
quantifications of the lowest concentration point in the standard curves
(0.1 ng/ml), specifically as the average plus six standard deviations; this
amounted to an LOQ of 0.19 ng/ml (signal/noise ratio ˃20). Accuracy
based on the same standard sample set was 8.8% and precision was
18.0%.
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2.3. Processing of tissue samples before LC-MS/MS analyses
In order to process the tissue samples such that their CBZ content
could be quantified, we developed a protocol for enzymatic digestion of
tissue followed by extraction and quantification of CBZ using the LC-
MS/MS method described above. The enzyme buffer consisted of
Dulbecco's Modified Eagle Medium (DMEM, Thermo Fisher Scientific,
USA, 41965039) with 1% (v/v) penicillin-streptomycin stock solution
(Sigma-Aldrich, P0781) to a final concentration of 100 U/ml penicillin
and 100 μg/ml streptomycin, 0.125mg/ml papain (Merck, F275644),
2.5 mg/ml trypsin (Sigma-Aldrich, T7409), 0.8mg/ml collagenase
(Sigma-Aldrich, C7926), 0.69mg/ml hyaluronidase (Sigma-Aldrich,
H3506) and 1% (v/v) Triton X-100 (Sigma-Aldrich, T-8787). To de-
termine the biodistribution of CBZ, frozen organs (liver, spleen, lymph
nodes, kidneys, tumors) were thawed and freshly prepared enzyme
buffer was added at 1ml per 50mg tissue; the entire organs were di-
gested. The samples were heated to 37 °C for 72 h with vortexing once a
day, until the tissue was completely dissolved. Stability of CBZ under
these conditions was verified by incubation of known concentrations of
the free drug. The tissue digests, as well as the plasma samples from the
animals, were diluted 10× in acetone before centrifugation; this has
the dual effect of both precipitating proteins and other macromolecules,
thus cleaning up the sample, and making sure all cabazitaxel is solu-
bilized. Internal standard (hexadeuterated CBZ) dissolved in acetone
was added to a final concentration of 10 ng/ml during the acetone di-
lution to correct for possible matrix effects.
2.4. Cell lines
Three commonly used breast cancer cell lines [18] were used. The
MDA-MB-231, (triple negative; Claudin low), was cultured in RPMI
1640; the MDA-MB-468 (triple negative; basal) and the MCF-7 (luminal
A) [18] cell lines were cultured in DMEM. All medium was fortified
with 10% (w/v) fetal calf serum albumin (Sigma) and 100 units/ml
penicillin/streptomycin (PenStrep®, Sigma). All cell lines were obtained
from ATCC and were routinely tested for mycoplasma. Cells growing in
24- or 96-well plates were incubated with serial dilutions of PEBCA-
CBZ, CBZ (non-encapsulated CBZ) dissolved in Tween-80 (Fluka)), and
PEBCA without CBZ for 24, 48 or 72 h at 37 °C in an atmosphere of 5%
CO2. The toxicity was assessed either by the commonly used MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cell via-
bility assay, by measuring cell proliferation based on [3H]thymidine
incorporation, by measuring protein synthesis by incorporation of [3H]
leucine and by measuring ATP levels using CellTiter Glo® .
2.5. MTT cell viability assay
The cells were incubated for 24, 48 and 72 h with the different NPs/
substances. The cell medium was then aspirated and exchanged with
100 μl of medium containing a final concentration of 250 μg MTT/ml.
The incubation was continued for 3 h at 37 °C for formation of the
formazan-particles, which were dissolved in DMSO with 1% (v/v)
NH4Cl. The absorbance was read in a plate reader (Biosys Ltd., Essex,
UK) at 570 nm, and background from absorbance at 650 nm was sub-
tracted.
2.6. Cell proliferation measured by [3H]thymidine incorporation
Incorporation of [3H]thymidine into DNA was used to estimate cell
proliferation. The cells were incubated for 24 h with the different NPs/
substances. The cell medium was then aspirated and substituted with
serum free cell medium containing [3H]thymidine (3 μg/ml; 75 μCi/
ml). The incubation was continued for 30min at 37 °C. The medium
was removed and 5% (w/v) trichloroacetic acid (TCA) was added. After
5min the cells were washed twice with TCA and solubilized with 200 μl
of 0.1M KOH, before mixing with 3ml scintillation fluid (Perkin Elmer,
USA). The radioactivity was counted for 1min in a scintillation counter
(Tri-Carb 2100TR, Packard Bioscience, USA).
2.7. Protein synthesis measured by [3H]leucine incorporation
To determine the impact of PEBCA-CBZ and CBZ on protein
synthesis, the cells were incubated with these substances for 24 h. The
cell medium was then aspirated, the cells washed once with leucine-free
HEPES medium (28mM HEPES, (4-(2-hydroxyethyl)-1-piper-
azineethanesulfonic acid) in MEM) and further incubated with leucine-
free HEPES medium containing [3H]leucine (2 μCi/ml) for 30min at
37 °C. The medium was removed and 5% (w/v) TCA was added to
precipitate proteins. After 5min the cells were washed again with 5%
(w/v) TCA and solubilized with 200 μl of 0.1M KOH, before mixing
with 3ml scintillation fluid and counting the radioactivity as described
above.
2.8. Cell viability estimated by measuring ATP
Viability of the cells was tested measuring the ATP levels by using
the CellTiter-Glo® (Promega,WI, USA) assay, as described by the sup-
plier. Cells were incubated with PEBCA-CBZ or CBZ for 72 h, thereafter
one half of the volume was removed, replaced with an equal volume of
the ATP reagent and gently mixed. After incubation for 10min the cell
lysate was transferred to a light-protected 96-well plate and lumines-
cence measured in a plate reader (Biosys Ltd., Essex, UK).
2.9. Treatment efficacy evaluation in nude mice
All animal experiments were approved and performed according to
the Norwegian Animal Research Authority (Permit number 15-136041)
and were conducted according to the regulations of the Federation of
European Laboratory Animal Science Association (FELASA). The mice
were kept under pathogen-free conditions, at constant temperature
(21.5 ± 0.5 °C) and humidity (55 ± 5%); 15 air changes/h and a 12 h
light/dark cycle. They had access to distilled water ad libitum, which
was supplemented with 17-β-estradiol at a concentration of 4mg/l
[19]. All mice used in this study were female athymic nude foxn1nu
mice (age 5–6weeks and body weights of 18–20 g), locally bred at the
Department of Comparative Medicine, Oslo University Hospital,
Norway. In all procedures where anesthesia was required 4% sevo-
fluran was used.
The orthotopically growing basal-like xenograft MAS98.12 has been
established in house [19] and was used as previously described [16].
When using the MDA-MB-231 cell line, 1.5 million cells were injected
into the mammary fat pad and growing tumors were used for sequential
implantation. As for the MAS98.12 model, 1–2mm3 pieces of healthy
tumor tissue were implanted bilaterally into the mammary fat pad of
female athymic mice. After the tumors reached approximately 5mm in
diameter, the mice were randomly assigned to the different treatment
groups (the average volume of each group was 49–57mm3).
All formulations were given twice (day 1 and day 4 after rando-
mization) as i.v. tail vein injections. PEBCA-CBZ NPs were given with a
dose of CBZ 15mg/kg and comparable amount of empty PEBCA NPs
(175mg/kg) as control. Non-encapsulated cabazitaxel was prepared as
a stock solution in Polysorbate 80 (40mg/ml) and further diluted with
13% (v/v) ethanol to a working solution of 10mg/ml CBZ. The injec-
tion solution was prepared directly before the administration by dilu-
tion of the working solution with 0.9% (w/v) NaCl. The same amount of
ethanol (1.2–1.4% (v/v)) was used as vehicle control; injection volumes
were in the range 200–290 μl. From the first day of treatment, tumor
diameter and body weight were measured twice weekly. Mice were
monitored daily for health status and were killed by cervical dislocation
if they became moribund or if tumor reached 1500mm3. The tumor was
measured by calipers and the tumor volume was calculated according
to the formula 0.5 x length x width2 and related to the tumor volume at
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start of treatment.
2.10. In vivo imaging
PEBCA NPs labeled with the lipophilic and fluorescent dye NR668
were used to study the biodistribution in MA98.12 bearing mice using
an IVIS® Spectrum in vivo imaging system (Perkin Elmer). Mice were
intravenously injected the same single dose PEBCA-CBZ or PEBCA
without drug as in the efficacy study. The batch containing CBZ has
somewhat larger particles than the batch not containing CBZ (Table
S1). The excitation/emission wavelength pair of 535/640 nm was found
to give the best signal-to-noise ratio and was thus used for imaging of
the NPs. Whole body images were obtained 1, 4, 24 and 96 h after in-
jection; the animals were then sacrificed by cervical dislocation and
organs were harvested. The organs were imaged ex vivo with the IVIS
scanner using the same settings as above. Relative signal intensity in the
organs was calculated, using Living Image software (Perkin Elmer), as
radiant efficiency (Emission light [photons/s/cm2/str]/ Excitation light
[μW/cm2]×10 [9]) per pixel of the region of interest, which was
drawn around the respective organ. Fluorescent measurements of the
PEBCA NPs used for in vivo imaging showed that the particles without
CBZ had a fluorescent intensity of 1.17 times that of the PEBCA NPs
containing CBZ and the data shown in Fig. 3C are corrected for this
difference.
2.11. Biodistribution and pharmacokinetics in blood
Blood and tissue samples were obtained following a single i.v. in-
jection of PEBCA-CBZ and non-encapsulated CBZ (15mg/kg) into the
tail vein of mice bearing the MAS98.12 tumor (n=3). Empty particles
(PEBCA) and saline were used as negative controls. The blood samples
were taken either per tail vein puncture (approximately after 2min and
thereafter at 1, 4 and 24 h after injection) or by terminal cardiac
puncture (24 and 96 h after injection) in Vacutainer tubes containing
EDTA (BD Biosciences, San Jose, CA, USA) and kept on ice. The 0–24 h
samples were collected consecutively from the same animals (n=3)
while samples after 96 h were obtained from separate mice (n=3). The
blood was centrifuged for 15min at 4 °C and 3400 x g, and the super-
natant plasma was collected and stored at −80 °C until LC-MS/MS
analysis. The animals were sacrified after 24 or 96 h and tissue samples
(tumors, livers, spleens, lymph nodes and kidneys) were harvested. The
organs were gently washed with saline and then snap frozen in liquid
nitrogen and stored at −80 °C until further processing and LC-MS/MS
analyses as described above. Statistical analyses were performed using
the t-test.
2.12. Immunohistochemistry
Tumors from MAS98.12 bearing mice were collected 96 h after a
single injection of the same substances as were injected in the
MAS98.12 efficacy study. The tumors were preserved in 4% (v/v) for-
malin and then paraffinized and sliced to prepare consecutive slides
(3 μm thick). The deparaffinization agent Neo-clear and mounting agent
Neo-mount were obtained from VWR (Radnor, PA, USA). Heat induced
epitope retrieval was performed by placing deparaffinized slides with
10mM sodium citrate buffer (pH 6.0) in water bath for 20min at
100 °C. Endogenous peroxidase activity was blocked by incubating
slides with 3% (v/v) hydrogen peroxide in Tris-buffered saline (TBS;
50 mM Tris-Cl, 150mM NaCl, pH 7.6). Sections were washed and
blocking of non-specific binding was performed with 3% (w/v) bovine
serum albumin (Roche diagnostics GmbH, Mannheim, Germany) in TBS
for 30min. Sections were then incubated for 60min with the primary
antibodies. Three different antibodies, i.e. anti-CD68 (1mg/ml;
ab125212, Abcam, Cambridge, UK), anti-CD206 (0.1 μg/ml; ab64693,
Abcam, Cambridge, UK), and anti-iNOS (0.5 μg/ml; ab15323, Abcam,
Cambridge, UK) were used to detect different populations of
macrophages. CD68 is a commonly used marker for the whole macro-
phage population [20,21], iNOS (inducible nitric oxide synthase) is a
marker for M1 macrophages (anti-tumorigenic and pro-inflammatory
macrophages) [22], and CD206 is a marker for M2 macrophages (pro-
tumorigenic and anti-inflammatory macrophages) [22]. TBS was used
for washing the slides between steps. Detection of primary antibodies
was performed using MACH 3 rabbit HRP-polymer detection kit ac-
cording to the manufacturer's protocol (Biocare Medical, Concord, CA,
USA). Signals were developed by incubation with the Chromogen so-
lutions provided with the Betazoid DAB Chromogen kit (Biocare Med-
ical). For counter staining a haematoxylin and 37mM ammonium hy-
droxide containing solution (Sigma-Aldrich, St. Louis, MO, USA) were
used.
Stained tissue sections were scanned (NanoZoomer HT, Hamamatsu
Photonics, Hamamatsu, Japan) using a 40× objective. The extent of
CD68, iNOS and CD206 was automatically scored using the
ImmunoPath software (Room4 Ltd., Crowborough, UK) [23]. The
tumor areas were marked manually, excluding necrotic areas as well as
blood vessels to avoid unspecific or false positive staining. The anno-
tated areas were then broken down to smaller frames per image of in-
terest for efficient processing. The annotated representative areas were
analyzed further by computerized image analysis. The image analysis
protocols were set up on randomly selected images from different tu-
mors to educate the software to differentiate between haematoxylin
stained blue negative staining and brown positive staining. The output
of the analysis provides the number of the positive pixel fraction and
the negative pixel fraction of total annotated area of the whole tumors.
2.13. Statistical analyses
To calculate the significance in the efficacy studies, the area under
the curve was calculated for each tumor and the mean values of the
groups were compared using the Welch unequal variance. To determine
whether there is a significant difference between the frequencies of the
tumor regression in the different treatment groups, we used the
Fischer's exact test. If not stated otherwise, an unpaired two-sided
Student t-test without Welch correction was used. The statistical ana-
lyses were performed using either GraphPad Prism (version 7.00 for
Windows, GraphPad Software, La Jolla, California, US) or Microsoft
Excel.
3. Results
3.1. Characterization of PEBCA particles
The particle size, polydispersity index (PDI) and zeta potential for
the batches used, were in the range of 148–227 nm (z-average),
0.04–0.19 and - (0.6–2.4) mV, respectively. The drug content in the
final particles was 6.0–8.6% (w/w), giving 2.0–3.4mg CBZ/ml in the
NP stock solutions (Table S1). The size of PEBCA NPs increased when
adding the drug CBZ (Table S1). The size distribution curves for the two
batches used for efficacy studies in the MAS98.12 tumor model and that
of CBZ (forming clusters in solution) are shown in Fig. 1.
3.2. PEBCA-CBZ inhibits tumor growth more efficiently than free CBZ in the
MAS98.12 mice model
To test the efficacy of the PEBCA NPs with incorporated CBZ in a
PDX model, MAS98.12 tumors were implanted into the mammary fat
pad of nude mice and treated with the drug-loaded particles (PEBCA-
CBZ), empty particles (PEBCA), non-encapsulated (free) CBZ and saline
as control (Fig. 2A). The injected dose was 2×15 mg CBZ/kg body
weight, which corresponds to a particle dose of 2×175 mg/kg
(Fig. 2A). Tumor growth was not affected by empty PEBCA NPs, but
markedly inhibited by CBZ. The effect was significantly more pro-
nounced when the drug was encapsulated in the NPs compared to free
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drug (Fig. 2A). Notably, in the PEBCA-CBZ treated group 6 out of 8
tumors went into complete remission while this was the case in only 2
out of 9 CBZ-treated tumors and none in the negative control groups
(Fisher's exact test (1-sided): p= 0.04; comparing PEBCA-CBZ with
CBZ).
To further evaluate differences in tumor growth between the four
groups, we calculated the area under the curve (AUC) for each in-
dividual tumor and compared the mean values of each treatment group.
The efficacy of PEBCA-CBZ is significantly better than treatment with
free CBZ (p= .02; Fig. S1). The toxicity of the different treatments
measured as body weight relative to the weight at treatment start is
shown in Fig. 2B. The two treatments with CBZ (non-encapsulated or
encapsulated as PEBCA-CBZ) caused a decline in body weight by ap-
proximately 15%, but one week after the last injection the effect of the
body weight was reversed. This tolerable body weight loss and the re-
covery time were comparable for PEBCA-CBZ and CBZ. Administration
of empty PEBCA NPs did not cause any toxic effect as estimated from
the body weights.
The efficacy of PEBCA-CBZ and non-encapsulated CBZ was also
studied in MDA-MB-231 tumor-bearing mice. In this model we did not
detect a significant difference between the two CBZ formulations, but a
delay in tumor growth was observed (Fig. S2). When compared to
MAS98.12, the CBZ (free and encapsulated drug) was less effective in
the MDA-MB-231 tumors. It was not possible to improve the efficacy by
increasing the dose, due to limiting systemic toxicity [8].
3.3. In vivo biodistribution of PEBCA particles
The biodistribution of the PEBCA NPs in MAS98.12 bearing mice
was studied by fluorescence imaging up to 96 h after injection of par-
ticles containing the fluorescent dye NR668. The mice were imaged
using the IVIS® Spectrum scanner after 1, 4, 24 and 96 h (Fig. 3A), and
then sacrificed such that organs could be harvested and visualized ex
vivo. The images of all organs harvested 24 h after injections are shown
in Fig. 3B, and the mean radiant efficiency relative to the pixel size of
the region of interest per organ is plotted in Fig. 3C. The images of
organs obtained at 1, 4 and 96 h are shown in Fig. S3. Injection of the
free NR668 dye did not give any detectable fluorescence with the wa-
velengths used (data not shown), thus indicating that the detected
signals are from PEBCA-bound NR668. The images shown in Fig. 3 and
Fig. S3 demonstrate a rapid uptake in all tissues shown; 24 h after in-
jection the strongest signals were observed in liver, spleen and lymph
nodes, although fluorescence also was easily detectable in tumors,
kidneys, hearts and lungs (Fig. 3C).
3.4. Pharmacokinetics and biodistribution of encapsulated and non-
encapsulated CBZ
PEBCA-CBZ and non-encapsulated CBZ (15mg/kg) were in-
travenously (i.v.) injected into the tail vein of mice bearing the
MAS98.12 tumor. Blood samples were taken approximately 2min after
injection, and 1, 4, 24 and 96 h after injection, and the plasma samples
were analyzed for CBZ using an LC-MS/MS method. The CBZ con-
centrations at almost all time points were at least 10-fold higher in mice
receiving PEBCA-CBZ compared to mice receiving free CBZ (Fig. 4A).
The plasma concentration/time curves for both PEBCA-CBZ and
CBZ indicate an initial distribution phase, followed by a terminal
elimination phase. The low number of data points did not allow de-
termination of distribution or elimination half-life through non-linear
regression. Interpolation based on the two first data points (up to 1 h)
indicate distribution half-lives in the range of approximately 50min
and 30min for PEBCA-CBZ and CBZ, respectively. Similarly, calculation
of the elimination half-lives based upon the mean values of the two last
time points (24 and 96 h) indicates half-lives of this phase of about 60 h
for both compounds. The higher plasma concentration observed after
administration of PEBCA-CBZ compared to CBZ suggests a lower dis-
tribution volume and lower total clearance for PEBCA-CBZ compared to
CBZ. This is consistent with the NP formulation being less able to escape
the vascular compartment, and elimination of NPs primarily through
the reticuloendothelial system.
Fig. 1. Size distribution of the batches used in the MAS98.12 efficacy study.
The size distributions for PEBCA-CBZ (the batch with size z-average of 215 nm
in Table S1) is shown in dark blue and for PEBCA (without drug; the batch with
z-average of 156 nm in Table S1) is shown in light blue. The size distribution of
CBZ, which forms clusters in solution, is shown in red. Intensity (%) on the y-
axis means percent intensity of the total scattered light. (For interpretation of
the references to colour in this figure legend, the reader is referred to the web
version of this article.)
Fig. 2. Treatment efficacy and toxicity studied in
mice bearing MAS98.12 PDX breast tumors. Tumor
growth inhibition (A) and body weight change (B)
after treatment. PEBCA-CBZ and CBZ were injected
2× 15mg CBZ/ kg body weight at day 33 and 36,
indicated by the red arrows. Empty PEBCA NPs
(same dose as PEBCA-CBZ) and saline were used as
negative controls (mean ± SEM; n=8–9 tumors/
5–6 mice). Tumor size is relative to the size mea-
sured at time of randomization. Non-palpable tumors
at day 57 after implantation are indicated as com-
plete remissions. The statistical p-value of Welch t-
test of areas under the curves is indicated (p=0.02).
(For interpretation of the references to colour in this
figure legend, the reader is referred to the web ver-
sion of this article.)
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The CBZ concentrations were measured in tumor, liver, spleen,
lymph nodes, and kidney following a single injection of PEBCA-CBZ and
CBZ (15mg/kg). The results obtained with samples taken 24 and 96 h
after injections are shown in Fig. 4B and C, respectively. The data are
given as ng CBZ/mg tissue; for researchers wanting to have data as %
ID/mg the injected dose was 0.27–0.30mg CBZ. The highest amount of
drug per mg tissue was obtained in spleen. However, when assuming
that the mass of liver is approximately 13 times that of spleen in mice
[24] the data in Fig. 4 indicates that the liver/spleen ratio of PEBCA-
CBZ is 2.1 at 24 h after injection and 4.4 at 96 h after injection, de-
monstrating that liver is taking up the largest part of these NPs. The
amounts of CBZ in the tumor samples measured as ng CBZ/mg tissue
were 20% (24 h) and 1.4% (96 h) of that in liver after injection of
PEBCA-CBZ.
The concentration of CBZ was significantly higher (t-test; p-
value< .01) in all tissues analyzed at 24 h following injection of par-
ticle bound (PEBCA-CBZ) as compared to free drug (CBZ), with the
largest differences observed in liver and spleen which contained the
highest amounts of PEBCA-CBZ. In the samples obtained 96 h after in-
jection, CBZ could be detected (i.e. being above the LOQ of the LC-MS/
MS method; calculated to be 0.19 ng/ml) in all tissues analyzed after
injection of PEBCA-CBZ. Following injection of free CBZ, the CBZ
content was below the LOQ for all tissues except tumor tissue 96 h after
injection, such that the CBZ content could be estimated in tumor tissue
only (Fig. 4C). The CBZ content measured in tumors 24 h after injection
of PEBCA-CBZ was approx. 1.2% of the injected dose. This was reduced
to approx. 0.5% at 96 h after injection. The amount of CBZ found in
tumors after injection of free CBZ was approximately half of that ob-
tained after injection of PEBCA-CBZ at both time points. When com-
paring the CBZ concentrations in the tissue samples obtained 24 and
96 h after injection of PEBCA-CBZ, there is a decrease in tumor, spleen
and kidney, and an increase in liver and lymph nodes from 24 to 96 h.
The only significant difference is the decrease in the MAS98.12 tumor
tissue (p= .02). Also, the CBZ concentration after injection of free CBZ
was significantly lower in tumors after 96 h when compared to 24 h
(p < .001). Plasma and tissue samples were also analyzed for CBZ
following injection of PEBCA NPs without CBZ; all these samples (si-
milar to those samples analyzed after injection of PEBCA-CBZ) were
below the LOQ of the analytical method.
3.5. Macrophage infiltration in treated MAS98.12 tumors
The infiltration of CD68 antibody stained macrophages into control
and treated MAS98.12 tumors was estimated using automatic quanti-
fication of scanned slides. An elevated number of tumor infiltrating
macrophages was observed in mice injected with PEBCA-CBZ or PEBCA
without drug compared to mice receiving free CBZ or saline, but the
differences did not reach statistical significance (Fig. 5A). Also the
marker of pro-inflammatory M1 macrophages (iNOS) demonstrated
increased macrophage infiltration into tumors of mice receiving
PEBCA-CBZ or PEBCA (Fig. 5B). However, the anti-inflammatory M2
macrophages subset, measured as CD206 positive cells, demonstrated
Fig. 3. Biodistribution of PEBCA particles containing the fluorescent dye NR668 measured in MAS98.12 tumor-bearing mice. Whole body images were obtained with
IVIS 1, 4, 24 and 96 h after i.v. administration of the NPs; colour scale on the right indicates radian efficiency × 109 (A). Ex vivo fluorescence images of isolated
organs were obtained 24 h after injection (B). Quantification of fluorescence intensity as relative radiant efficiency per region of interest pixel data of tissues collected
24 h after injection (C). Mean values obtained for 2 animals; error bars show SD values. PEBCA-CBZ: PEBCA containing CBZ and NR668; PEBCA: PEBCA containing
NR668, but not CBZ. LNs: lymph nodes. The tumor data are enlarged in the inset.
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increased infiltration compared to the saline control only in tumors
receiving PEBCA (Fig. 5C). Furthermore, the tumors of mice receiving
PEBCA-CBZ showed significant lower levels (mean value of 23%) of this
pro-tumorigenic macrophage population than tumors receiving PEBCA
alone (p < 0.001; Fig. 5C).
3.6. In vitro cell studies
We tested cellular toxicity of PEBCA-CBZ, free CBZ and PEBCA
without drug in three cell lines, specifically MDA-MB-231, MDA-MB-
468 and MCF-7, measuring both cell proliferation by incorporation of
[3H]thymidine after 24 h and cell viability after 72 h by using the MTT
assay. PEBCA-CBZ and CBZ were significantly more toxic than PEBCA
without drug for all cell lines (range 130–350 fold), but there was no
difference in the toxic effect of PEBCA-CBZ and CBZ in any of these test
systems in any cell line (Fig. S5). It was also apparent that a small
Fig. 4. CBZ concentrations in plasma and organs measured with LC-MS/MS
after administration of 15mg CBZ/kg. Plasma concentration measured as
function of time (A). CBZ concentrations in tumors and organs measured after
24 h (B) and 96 h (C). LNs: lymph nodes. Data shown are mean values± SD
(n=3). Note that logarithmic scales are used on all y-axes.
Fig. 5. Macrophage infiltration in treated MAS98.12 tumors. The macrophage
infiltration was measured in the MAS98.12 tumors 96 h after injection of saline
(control), PEBCA NPs (without drug), free CBZ, and PEBCA-CBZ. (A): The total
population of infiltrated macrophages was quantified using an antibody to
CD68. (B): The population of anti-tumorigenic (pro-inflammatory) macro-
phages was quantified using an antibody to iNOS. (C): The population of pro-
tumorigenic (anti-inflammatory) macrophages was quantified with an antibody
to CD206. Data for the whole tumors are shown as mean ± SEM (n=3 for
control samples; n=4 for PEBCA and n=5 for CBZ and PEBCA-CBZ). Asterisks
indicate statistical significance obtained by unpaired parametric t-test, where
p < 0.0005 is marked with *** and p < 0.0001 is marked with ****.
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fraction (10–20%) of the cells in all cell lines tested survived even very
high CBZ concentrations when using the MTT assay after incubation for
72 h. The toxicity of PEBCA-CBZ and free CBZ were also tested in all
three cell lines using two other test systems. The effect on protein
synthesis (incorporation of [3H]leucine) was measured following 24 h
of incubation, and the ATP levels (CellTiter-Glo®) were measured after
72 h. The results obtained with these test systems (data not shown)
were very similar to those shown in Fig. S5. The MTT assay was also
performed on MDA-MB-231 cells after 24 and 48 h of incubation with
similar results to those shown after 72 h of incubation (Fig. S5), al-
though the toxic effect was smaller after these shorter incubation times
(data not shown).
4. Discussion
The PEBCA NPs containing CBZ demonstrated a remarkable good
therapeutic effect in the triple negative PDX mouse model, where
complete remission was obtained in 6 out of 8 tumors following two
injections of 15mg CBZ/kg (Fig. 2A). Several possible explanations for
the advantageous effect of PEBCA-CBZ versus free CBZ can be envi-
sioned, and the obtained data point at least to the following factors: The
longer circulation in blood and higher concentration of the drug in the
tumor (Fig. 4) and the higher ratio of anti-tumorigenic (anti-iNOS la-
beled) macrophages to pro-tumorigenic (anti-CD206 labeled) macro-
phages [22,25] in the treated tumors (Fig. 5).
The quantification of CBZ in blood plasma clearly show a longer
circulation time when the drug was incorporated in the NPs, with at
least a 10-fold higher concentration in mice receiving PEBCA-CBZ
compared free CBZ (Fig. 4A). When evaluating such data it is important
to remember that the CBZ incorporated in NPs does not have a ther-
apeutic effect before being released. Thus, release of the drug by dif-
fusion and/or biodegradation of the NPs are necessary to obtain a good
therapeutic effect as observed in the MAS98.12 model.
The in vivo fluorescence imaging data obtained with PEBCA NPs
labeled with NR668 demonstrates accumulation of the fluorescence in
the same tissues as those where CBZ was found to be present. As ex-
pected, these data show that most of the NPs ended up in the liver. The
liver/spleen ratio of the fluorescence per pixel measured 24 h after in-
jection was estimated to be 2.9 for NPs without CBZ and 2.4 for NPs
with CBZ, whereas the ratio of total CBZ content in liver to spleen was
calculated to 2.1 based on the MS analyses. Although one should be
careful in interpreting the quantitative data from the fluorescent ima-
ging (based upon per pixel measurements) the biodistribution data,
obtained with two different methods, showed similar results. Our ob-
servations that injection of free NR668 did not give any measurable in
vivo signal, the report that NR668 did not leak from NPs with a similar
composition [26], and the different kinetics observed for PEBCA-CBZ
and CBZ (Fig. 4A), indicate that most of the CBZ and NR668 are en-
closed within the NPs 24 h after injection. Therefore, the biodistribution
of these low molecular substances seems to represent well the dis-
tribution of the PEBCA NPs at this time point. In another study with
comparable NPs, but using another PEGylation and fluorescent marker,
a liver/spleen ratio of 5.3 was reported 6 h after injection [27]. In this
study, the mean fluorescent signal obtained in the tumors 24 h after
injection was 12% of that in liver for the NPs not containing CBZ and
3% for the NPs containing CBZ. The higher fluorescence obtained fol-
lowing injection of PEBCA NPs without drug than for NPs containing
CBZ (Fig. 3A,B) may in part be due to the somewhat larger size of the
NPs with drug (Table S1).
Macrophages are the most abundant immune cells in mammary
tumors. Tumor associated macrophages (TAMs) were originally thought
to exert anti-tumor activities, but increasing clinical and experimental
evidence show that TAMs also may promote tumor progression and
influence anticancer drug responses [28–30]. The pro-tumorigenic
macrophages are known as alternatively activated and referred to as
anti-inflammatory (M2-type), whereas the classically activated pro-
inflammatory (M1-type) macrophages exhibit anti-tumorigenic prop-
erties [31,32]. Plasticity is a hallmark of the macrophage population
and dynamic changes in their phenotype define the different subtypes
[28]. A set of markers is usually recommended for a comprehensive
characterization of the whole population [22,33]. In the present study
we have used the well-accepted nitric oxide synthase (iNOS) for de-
tection of the M1 phenotype and mannose receptor (CD206) to define
the M2-type [22,33].
The TAMs are influenced by the context, e.g. by factors in the mi-
croenvironment or externally added anticancer drugs. Interestingly, the
effect of docetaxel has been shown to partly depend upon depletion of
M2 macrophages and expansion of M1 macrophages in models of breast
cancer [34]. In contrast, we did not observe any response in the mac-
rophage populations upon treatment with free CBZ, another taxane,
despite efficient growth retardation. However, treatment with PEBCA
encapsulated CBZ, resulted in significant improved anti-tumor efficacy,
and complete remission in 75% of the tumors. Even though the number
of tumors used for immunohistochemical quantification is small, our
data suggest two possible mechanisms that might contribute to the
good effect. First, a trend towards elevated inflammation in tumors
upon treatment with PEBCA NPs (with or without drug) was observed.
This may imply a role of PEBCA NPs in homing anti-tumorigenic M1
macrophages into the tumors, and thus further support the effect of
CBZ. Secondly, we also showed that PEBCA-CBZ treatment significantly
reduced CD206 expression in tumors compared to treatment with NPs
without drug, which may point towards depletion of pro-tumorigenic
macrophages.
Recently it was published that M2 macrophages show a vigorous
endocytic uptake by macropinocytosis, whereas this uptake was vir-
tually inactive in the M1 macrophages [35]. Furthermore, another
study showed that the M2 macrophages use endocytosis to degrade
collagen and promote tumor growth in solid tumors [36]. We speculate
that the decrease in M2 macrophages observed after treatment with
PEBCA-CBZ, and the concomitant pronounced effect on tumor growth,
may be related to the macropinocytic uptake of PEBCA-CBZ and sub-
sequent killing of these M2 macrophages. Thus, the inherent properties
of M1 and M2 macrophages and selective toxic effect of drug containing
particles on M2 macrophages may increase the efficacy of the treat-
ment. It has earlier been published that driving TAMs towards M1
polarization (increasing the ratio of M1/M2 macrophages) has shown
promising therapeutic effects in mice cancer models [36].
The effect of PEBCA-CBZ and free CBZ was also examined in or-
thotopically growing MDA-MB-231 tumors without showing the same
efficacy as in the MAS98.12 PDX model. Since the influence of these
NPs are based on the so-called EPR effect [3], the tumor vasculature is
supposed to be a critical factor. We have earlier shown that the basal-
like MAS98.12 tumor has a higher vascularization than the luminal-like
MAS98.06 tumor [37,38]. Although angiogenesis also has been visua-
lized in MDA-MB-231 tumors in mice [39], the difference in vascular-
ization of the MAS98.12 and MDA-MB-231 tumors is less well char-
acterized. However, in two previously published studies, the blood
volume constituted 2.4% of the tumor volume 5weeks after inoculation
of MDA-MB-231 [39] and 5.9% at 5 weeks after transplantation of
MAS98.12 [40], suggesting more efficient vascularization in the latter
model.
Both the fluorescence in vivo imaging data and the quantification of
CBZ in tissue samples clearly demonstrate accumulation of the PEBCA
NPs in lymph nodes (Fig. 3B,C and Fig. 4B). Accumulation of drugs or
imaging agents in lymph nodes was recently reviewed [41,42], sug-
gesting a benefit of injecting very small NP [43,44]. A study reported
accumulation into lymph nodes of particles similar to those used in the
present study, i.e. poly(butylcyanoacrylate) modified with Pluronic
F127 and loaded with vincristine [45]. As these NPs were shown to
rapidly release vincristine and vincristine also accumulated in lymph
nodes following injection of the non-encapsulated drug [45], it is dif-
ficult to evaluate to which extent these NPs actually accumulated in the
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lymph nodes. Delivery of drug to lymph nodes has been discussed for
treatment of metastasizing tumors [41,46]. Since local lymph nodes are
the first site of breast cancer metastasis, and also a significant distant
metastatic site, in particular in the aggressive triple negative basal like
breast cancer [47], accumulation of PEBCA-CBZ in lymphatic tissue
may be an important feature of such treatment.
In summary, the PEBCA-CBZ NPs seem promising for treatment of
breast cancer, but further preclinical studies are necessary to show a
beneficial effect of PEBCA-CBZ in metastatic cancer models.
Furthermore, the observation that PEBCA seems to enhance in-
tratumoral infiltration of anti-tumorigenic macrophages might be of
general value and should be further investigated, either by using such
NPs as an immune modulator or a vehicle able to enhance the ther-
apeutic effect of encapsulated drugs.
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